Syndax Pharmaceuticals said its experimental menin inhibitor met the primary endpoint in a pivotal trial for certain leukemia patients, and it’s planning a regulatory filing …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
If Medicare Part D narrowly defines cardiovascular disease, the majority of patients would remain ineligible while new federal spending could still exceed $10 billion
The FDA is currently reviewing midomafetamine capsules — an MDMA-containing therapeutic — as a potential post-traumatic stress disorder treatment to be used in combination with
As the head of the trade group BIO and a parent to children with a rare disease, John Crowley is personally and professionally at the